Stock Movers Eli Lilly Shares Sink, Qualcomm's Tepid Forecast, Carrier Global Rises
May 1, 2025
Eli Lilly's shares took a dive after CVS dropped its weight-loss drug, raising concerns about competition. Qualcomm's revenue forecast disappointed investors, hinting at challenges from tariffs. Meanwhile, Carrier Global thrived by tackling tariff issues with strategic pricing, boosting its profit outlook. The conversation also highlights the growing need for effective indoor climate control in the face of rising temperatures, making a compelling case for the HVAC industry.
AI Snips
Chapters
Transcript
Episode notes
Eli Lilly Faces Competitive Setback
- Eli Lilly shares dropped about 10% after CVS Health dropped its weight-loss drug Zepbound from its preferred list.
- This move broadens access to rival Novo Nordisk's Wegovy, impacting investor expectations around growth for Eli Lilly.
Qualcomm's Tepid Revenue Forecast
- Qualcomm gave a cautious revenue forecast slightly below analyst expectations.
- Concerns persist about tariffs negatively impacting demand for Qualcomm's smartphone chips.
Carrier's Tariff Mitigation Strategy
- Carrier Global has fully mitigated its tariff exposure largely through price increases and supply chain adjustments.
- This strategy boosted its full-year profit outlook and caused a significant stock price jump.